Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT05654922

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

Led by Renovion, Inc. · Updated on 2025-12-09

100

Participants Needed

20

Research Sites

185 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this Phase 3 clinical trial is to compare ARINA-1 (a nebulized immunomodulatory agent) plus Standard of Care vs Standard of Care alone. The main question it aims to answer are: * Evaluate the effectiveness of ARINA-1 in preventing bronchiolitis obliterans syndrome (BOS) progression in participants with a bilateral lung transplant * To evaluate the effectiveness of ARINA-1 on improving quality of life decline and preventing or delaying the use of augmented immunosuppression in participants with pre-BOS relative to SOC. Participants will have clinic visits at screening, randomization (day 1) and weeks 4, 12, 18, and 24. After week 24, participants will have clinic visits at weeks 32, 40, and 48. Participants will also have a telehealth visit on day 2 and phone calls to assess adverse events (AEs), serious adverse events (SAEs), and review patient education will occur during weeks 5, 8, 36, and 44.

CONDITIONS

Official Title

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Bilateral lung transplant more than 12 months before randomization
  • Age between 18 and 75 years at consent
  • Routine follow-up at enrolling site
  • Willing and able to comply with visit schedule and home requirements
  • 10-24% decrease in FEV1 from post-transplant baseline within last 12 months
  • Able to provide informed consent
  • Stable azithromycin use for more than 4 weeks before screening
  • Stable 2- or 3-agent immunosuppression regimen including steroid and calcineurin inhibitor for over 4 weeks before screening
  • Women of childbearing potential must agree to reliable birth control during the study
Not Eligible

You will not qualify if you...

  • Positive urine pregnancy test at screening and baseline
  • Active congestive heart failure or symptomatic coronary artery disease above grade 3 (NYHA criteria)
  • Restrictive allograft syndrome shown by chest X-ray or CT scan
  • Advanced bronchiolitis obliterans syndrome with more than 24% decrease in FEV1
  • Probable antibody-mediated rejection diagnosed within 12 months before baseline
  • Donor-specific antibodies identified less than 6 months before baseline
  • Unresolved diffuse alveolar damage
  • Currently receiving mechanical ventilation
  • Chronic kidney disease stage IV or higher, including dialysis
  • Starting or changing maintenance immunosuppression therapy within 30 days before baseline
  • Starting or changing mTOR therapy less than 3 months before screening
  • Starting or changing antibiotic, antiviral, or antifungal therapy less than 14 days before baseline
  • Use of alemtuzumab less than 6 months before baseline
  • Use of anti-thymocyte therapies or photopheresis less than 90 days before screening
  • Starting multivitamins or supplements containing vitamin C, glutathione, or N-acetylcysteine less than 90 days before baseline
  • Unstable significant comorbidities
  • Allergy or previous adverse reaction to azithromycin
  • Diagnosis of dynamic collapse or tracheobronchomalacia less than 90 days before baseline
  • Participation in other interventional clinical studies less than 30 days before baseline
  • Diagnosis of ARAD within 6 weeks before screening
  • Use of belatacept less than 6 months before screening
  • Bronchial stents or cryotherapy treatment within 12 months before screening, or stent removal within last 3 months before screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 20 locations

1

Dignity Health - St. Joseph's Hospital and Medical Center

Phoenix, Arizona, United States, 85013

Withdrawn

2

University of California Los Angeles School of Medicine

Los Angeles, California, United States, 90095

Actively Recruiting

3

University of California San Diego Health

San Diego, California, United States, 92103

Actively Recruiting

4

Advent Health

Orlando, Florida, United States, 32803

Actively Recruiting

5

University of South Florida

Tampa, Florida, United States, 33606

Actively Recruiting

6

Loyola University Medical Center

Maywood, Illinois, United States, 60153

Actively Recruiting

7

University of Iowa Hospital

Iowa City, Iowa, United States, 52242

Actively Recruiting

8

Johns Hopkins Hospital

Baltimore, Maryland, United States, 21287

Actively Recruiting

9

University of Minnesota Medical School

Minneapolis, Minnesota, United States, 55455

Withdrawn

10

Washington University School of Medicine

St Louis, Missouri, United States, 63110

Actively Recruiting

11

Columbia University Irving Medical Center

New York, New York, United States, 10032

Actively Recruiting

12

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

13

The Ohio State University Wexner Medical Center

Columbus, Ohio, United States, 43221

Actively Recruiting

14

Temple University Hospital

Philadelphia, Pennsylvania, United States, 19122

Not Yet Recruiting

15

Medical University of South Carolina

Charleston, South Carolina, United States, 29452

Actively Recruiting

16

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 45390

Actively Recruiting

17

Baylor Scott and White Research Institute

Dallas, Texas, United States, 75246

Actively Recruiting

18

Baylor St. Luke's Medical Center

Houston, Texas, United States, 77030

Actively Recruiting

19

Houston Methodist Hospital

Houston, Texas, United States, 77030

Actively Recruiting

20

Inova Fairfax Hospital

Falls Church, Virginia, United States, 22042

Actively Recruiting

Loading map...

Research Team

C

Carolyn Durham, PhD

CONTACT

W

Will Anderson

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant | DecenTrialz